Abstract
Breast cancer and osteoporosis are common diagnoses in women. Breast cancer survival has improved due to earlier detection and improved treatments. As most breast cancers are estrogen receptor positive, treatment is often aimed at altering the hormonal environment. Both pre and postmenopausal women undergoing these therapies are at risk for bone loss. The patient's health care team ought to have an awareness of the potential for breast cancer treatments to accelerate bone loss. Women with early stage breast cancer are treated with curative intent and, therefore, maintaining bone health is important and is part of the survivorship care to ensure an optimal quality of life.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Adult
-
Aged
-
Aromatase Inhibitors / adverse effects*
-
Aromatase Inhibitors / pharmacology
-
Aromatase Inhibitors / therapeutic use
-
Bone and Bones / drug effects*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / mortality
-
Diphosphonates / therapeutic use
-
Dose-Response Relationship, Drug
-
Female
-
Humans
-
Middle Aged
-
Osteoporosis / drug therapy
-
Osteoporosis / epidemiology*
-
Osteoporosis / prevention & control
-
Quality of Life
-
Risk Factors
-
Selective Estrogen Receptor Modulators / adverse effects*
-
Selective Estrogen Receptor Modulators / pharmacology
-
Selective Estrogen Receptor Modulators / therapeutic use
-
Survival Rate
Substances
-
Aromatase Inhibitors
-
Diphosphonates
-
Selective Estrogen Receptor Modulators